Cesari et al. [99], however, observed no significant interactions between sarcopenia and obesity with CRP, IL-6 or plasminogen activator inhibitor type 1, the primary inhibitor of the fibrinolytic process, in 286 elderly patients aged ≥55 years with a high CVD risk profile. Here, CRP is linked to sarcopenia.